Work

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma

Year: 2025

Type: article

Abstract: Modality treatment including surgery, chemotherapy, radiation and immunotherapy was considered as standard strategy for tonsillar squamous cell carcinoma (TSCC). We reported a case of a 78-year-old man under severe underlying medical conditions who diagnosed with human papillomavirus (HPV)-positive and programmed death ligand 1 (PD-L1)-positive TSCC. He was administered camrelizumab combined with gemcitabine (GEM) for 8 cycles with partial response. Then, we gave him concurrent nanoparticle albumin-bound paclitaxel (nab-paclitaxel)-based chemoradiation. Eventually, this patient achieved complete response without severe adverse events. After a 12-month follow-up, he had no recurrence or metastasis.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2025.1528198

Authors: Xuesong Li, Bianhong Wang, Hao Liu, Zhuo Yu

Institutions: Beijing Tsinghua Chang Gung Hospital, Tsinghua University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801